Tetrapyrroles and derivatives
Abcam Nocodazole, Microtubule inhibitor, 5MG
MW 301.32 Da, Purity >98%. Microtubule inhibitor. Rapidly depolymerises microtubules in vivo and inhibits tubulin polymerisation in vitro. Inhibits mitosis. Also reduces stem cell pluripotency factors Oct 4 and Nanog.
The product is subject to the following: Abcam Restricted Use Statement
![Abcam [Pyr1]-Apelin 13, endogenous apelin receptor (APJ) agonist, 1MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/502583378.JPG-250.jpg)
Abcam [Pyr1]-Apelin 13, endogenous apelin receptor (APJ) agonist, 1MG
MW 1533.8 Da, Purity >95%. [Pyr1]-Apelin 13, endogenous apelin receptor (APJ) agonist. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam A 943931 dihydrochloride, H4 receptor antagonist, 10MG
MW 368.3 Da, Purity >99%. Potent and selective H4 receptor antagonist (pKi = 7-8). Shows anti-inflammatory and analgesic effects *in vivo.* Orally active.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CK 666, Actin polymerization inhibitor, 10MG
MW 296.3 Da, Purity >99%. Potent inhibitor of actin polymerization. Inhibits the Arp2/3 (IC₅₀ = 17 μM), SpArp2/3 (IC₅₀ = 5 μM) and HsArp2/3 complexes (IC₅₀= 4 μM) by preventing a shift into an active conformation.
The product is subject to the following: Abcam Restricted Use Statement
Abcam omega-Agato x in IVA, Ca2+ channel blocker (P and Q type), 100UG
MW 5202 Da. omega-Agatoxin IVA, Ca2+ channel blocker (P and Q type). Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB 203580, p38 MAPK inhibitor, 10MG
MW 377.4 Da, Purity >99%. SB 203580, p38 MAPK inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SCD1 Inhibitor, SCD1(stearoyl-CoA desaturase 1) inhibitor, 1MG
MW 387.9 Da, Purity >99%. Potent, selective SCD1 (stearoyl-CoA desaturase 1) inhibitor (IC₅₀ = 4.5 nM). Inhibits the conversion of saturated, long-chain fatty acyl-CoAs to monounsaturated, long-chain fatty acyl-CoAs in vitro, when heptadecanoic acid and palmitic acid are used as the substrate (IC₅₀ = 7.9 and 6.8 nM, respectively). Active in vivo. Orally bioavailable.
The product is subject to the following: Abcam Restricted Use Statement
Abcam C59, Wnt Antagonist, Wnt signaling pathway inhibitor, 1MG
MW 379.5 Da, Purity >97%. Potent Wnt signaling pathway inhibitor. Inhibits porcupine (PORCN) required for Wnt palmitoylation, secretion, and biological activity. Inhibits Wnt-mediated transcription (IC₅₀ = 74 pM) and cell proliferation. Active in vivo..
The product is subject to the following: Abcam Restricted Use Statement
Abcam Necrostatin-1, necroptosis inhibitor, 50MG
MW 259.33 Da, Purity >99%. Potent, specific necroptosis inhibitor (EC₅₀ = 490 nM). Selective allosteric inhibitor of death domain receptor-associated adaptor kinase RIP1 in vitro (EC₅₀ = 182 nM). Caspase independent, programmed necrosis pathway.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Kynurenic acid sodium salt, Endogenous ionotropic / nicotinic antagonist, 1G
MW 211.15 Da, Purity >99%. Endogenous antagonist at ionotropic, glycine and α7 nicotinic receptors. Neuroprotective in vivo. Soluble in 1 ml water to give specified mM/ml concentration. Find out more.
The product is subject to the following: Abcam Restricted Use Statement
Abcam beta-Amyloid Peptide (42-1) (human), Inactive control, 1MG
MW 4514 Da. beta-Amyloid Peptide (42-1) (human), Inactive control. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dorsomorphin (Compound C), AMP-kinase inhibitor, 10MG
MW 399.5 Da, Purity >99%. Potent, selective and reversible inhibitor of AMP-kinase (Ki = 109 nM). Inhibits AMPK activation induced by AICAR (ab120358) and metformin (ab120847). Selective inhibitor of bone morphogenetic protein (BMP) type I receptors (ALK2, ALK3 and ALK6). Does not affect ZAPK, SYK, PKCθ, PKA and JAK3. Cell-permeable. Also available in a water soluble form (Dorsomorphin dihydrochloride - ab144821).
The product is subject to the following: Abcam Restricted Use Statement
Abcam x E-991 dihydrochloride, KCNQ channel blocker; blocks M current, 50MG
MW 449.4 Da, Purity >99%. Potent and selective blocker of KCNQ voltage-gated potassium channels. Blocks M current. (IC₅₀ values are 0.98 μM (M-current), 0.71 μM (KCNQ 2), 0.75 μM (KCNQX 1), >100 μM (Kv1.2) and >43 μM (Kv4.3). Potent pulmonary vasoconstrictor. Cognitive enhancer following oral administration in vivo.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Endothelin-1 (human, porcine), Vasoconstrictor peptide, 100UG
MW 2491.9 Da. Endothelin-1 (human, porcine), Vasoconstrictor peptide. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement